(Z) -Orantinib ((Z) -SU6668) is a potent, selective, orally active and ATP competitive inhibitor of Flk‐1/KDR, PDGFRβ, and FGFR1, with IC50s of 2.1, 0.008, and 1.2 μM, respectively. (Z) -Orantinib is a potent antiangiogenic and antitumor agent that induces regression of established tumors[1][2].